MEFS Exchange course & Symposium- ASRM2012

Date: October 23, 2012

Time: 4:15 pm - 6:15 pm

Location: Room 21 - San Diego Convention Center

Presenters

Suheil J. Muasher, M.D. (Chair), The Muasher Center for Fertility and IVF

James M. Goldfarb, M.D., Cleveland Clinic

Paul Devroey, M.D., Ph.D., Centre for Reproductive Medicine, Brussels

Botros B. Rizk, M.D., University of South Alabama

An OHSS-Free IVF Clinic: Should This Be a Goal and Is It Possible?

Needs Assessment and Description
Ovarian hyperstimulation syndrome (OHSS) is one of the most morbid complications of in vitro fertilization (IVF) treatment with an estimated mortality rate of 3 per 100,000 stimulated cycles. The incidence that is usually quoted to patients is 2% to 3%, but it is much higher in patients who are young, have a lean body mass and are hyper-responders (more than 15 oocytes recruited) to stimulation. This live course will educate practitioners on the recognition of patients at increased risk so that all measures are taken to prevent OHSS. IVF success should be defined not only by successful live births but also by eliminating OHSS in patients at risk.

Learning Objectives
At the conclusion of this session, participants should be able to: 

1.     Identify patient profiles that are at risk of developing OHSS. 

2.     Assess measures that will help eliminate the syndrome. 

3.     Measure success from IVF by live births as well as by absence of OHSS.

ACGME Competency
Medical Knowledge

TEST QUESTION:
After participating in this session, in my practice I will: 

1.     Use the same dosage of gonadotropins for all my IVF patients. 

2.     Strive to recruit the maximum number of oocytes for all patients. 

3.     Use milder forms of stimulation in patients at risk for OHSS. 

4.     Not worry about OHSS as it is very rare and can be treated successfully in most patients. 

5.     Not applicable to my area of practice.